Objective:

To support the commercialization of the BD Libertas™ wearable injector for self-administered therapies.

Key Findings:

• The BD Libertas™ wearable injector supports subcutaneous administration of high-dose biologics.
• The collaboration aims to enhance supply chain readiness for biopharma companies.
• The integration of BD technology with ten23 services facilitates smoother regulatory pathways.

Interpretation:

The partnership enhances the development and commercialization of self-administered therapies, potentially improving patient experience and treatment accessibility.

Limitations:

• The article does not provide specific data on the expected impact of the collaboration on market outcomes.
• No information on potential challenges or risks associated with the implementation of the wearable injector.

Conclusion:

The collaboration between ten23 health and BD aims to streamline the transition of biologics from intravenous to subcutaneous delivery, enhancing patient usability and market readiness.